|Bid||58.03 x 1400|
|Ask||58.00 x 800|
|Day's range||55.33 - 61.39|
|52-week range||50.50 - 100.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||205.04|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Inari Medical's (NARI) first-quarter results benefit from significant progress made across all of its growth drivers.
Joining me on today's call are Bill Hoffman, president and chief executive officer; and Mitch Hill, chief financial officer. This call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 25% and 4.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?